Skip to main content
Home > Week in Review > Regulatory

Chronological Index of BioCentury, Week in Review: Regulatory

BioCentury, Week in Review Current Issue
  • Benlysta belimumab regulatory update

    Human Genome Sciences Inc. (NASDAQ:HGSI), Rockville, Md. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Benlysta belimumab (formerly LymphoStat-B) Business: Autoimmune The Scottish Medicines Consortium …

    Published on 4/23/2012
  • Bronchitol mannitol regulatory update

    Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia Product: Bronchitol mannitol Business: Pulmonary The European Commission approved an MAA from Pharmaxis for Bronchitol mannitol for use in cystic fibrosis…

    Published on 4/23/2012
  • CK-2017357 regulatory update

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: CK-2017357 Business: Neurology FDA granted Fast Track designation for Cytokinetics' CK-2017357 to treat amyotrophic lateral sclerosis (ALS). The fast…

    Published on 4/23/2012
  • Delamanid regulatory update

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Delamanid (OPC-67683) Business: Infectious EMA disclosed that an MAA from Otsuka for delamanid is under review to treat tuberculosis (TB) infection. Delamanid is a …

    Published on 4/23/2012
  • Edurant rilpivirine regulatory update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Edurant rilpivirine (TMC278); Eviplera (Complera - U.S.) emtricitabine/tenofovir/rilpivirine Business: …

    Published on 4/23/2012
  • Eylea aflibercept ophthalmic solution regulatory update

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Eylea aflibercept ophthalmic solution (VEGF Trap-Eye) Business: Ophthalmic Regeneron said Centers for …

    Published on 4/23/2012
  • Flutiform fluticasone/formoterol regulatory update

    SkyePharma plc (LSE:SKP), London, U.K. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Mundipharma International Ltd., Cambridge, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Flutiform …

    Published on 4/23/2012
  • Gilenya fingolimod regulatory update

    Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Gilenya fingolimod (FTY720) Business: Autoimmune EMA and FDA updated the label for …

    Published on 4/23/2012
  • Glivec regulatory update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Glivec (Gleevec - U.S.) imatinib (QTI571) Business: Cancer The Scottish Medicines Consortium recommended the restricted use of Novartis' Glivec imatinib on …

    Published on 4/23/2012
  • Halaven eribulin mesylate regulatory update

    Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: Halaven eribulin mesylate (E7389) Business: Cancer Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that breast cancer drug …

    Published on 4/23/2012
  • Hematopoietic stem cell gene therapy regulatory update

    Genethon, Evry, France Product: Hematopoietic stem cell gene therapy Business: Inflammation European Commission granted Orphan Drug designation for the not-for-profit's autologous hematopoietic stem cell gene therapy to…

    Published on 4/23/2012
  • Humira adalimumab regulatory update

    Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Humira adalimumab Business: Autoimmune The European Commission approved Humira adalimumab to treat …

    Published on 4/23/2012
  • HyQvia regulatory update

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: HyQvia, HyQ Business: Hematology Halozyme and partner Baxter said FDA needs additional …

    Published on 4/23/2012
  • Jakavi regulatory update

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Jakavi (Jakafi) ruxolitinib (INCB18424) Business: Hematology EMA's CHMP issued a positive opinion recommending …

    Published on 4/23/2012
  • KeyPath MRSA/MSSA Blood Culture Test-BT regulatory update

    Microphage Inc., Longmont, Colo. Product: KeyPath MRSA/MSSA Blood Culture Test-BT Business: Diagnostic FDA granted 510(k) clearance to include the use of 4 BD Bactec blood culture bottles for Microphage's KeyPath MRSA/…

    Published on 4/23/2012
  • Nonacog gamma regulatory update

    Inspiration Biopharmaceuticals Inc., Cambridge, Mass. Product: Nonacog gamma (IB1001) Business: Hematology Inspiration submitted a BLA to FDA for IB1001 to treat and prevent bleeding in patients with hemophilia B. The …

    Published on 4/23/2012
  • Ocriplasmin regulatory update

    ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Ocriplasmin (formerly Microplasmin) Business: Ophthalmic As expected, ThromboGenics resubmitted a BLA for ocriplasmin to treat symptomatic vitreomacular …

    Published on 4/23/2012
  • PC111 regulatory update

    PinCell s.r.l., Modena, Italy Product: PC111 Business: Autoimmune The European Commission granted Orphan Drug designation for PinCell's PC111 to treat pemphigus. The human mAb against Fas ligand (TNF superfamily, member…

    Published on 4/23/2012
  • Pliaglis regulatory update

    Nuvo Research Inc. (TSX:NRI), Mississauga, Ontario Product: Pliaglis Business: Neurology Nuvo said partner Galderma S.A. (Lausanne, Switzerland) received a complete response letter from FDA for an sNDA for Pliaglis …

    Published on 4/23/2012
  • RoActemra tocilizumab regulatory update

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RoActemra tocilizumab (RG1569) Business: Autoimmune The Scottish Medicines Consortium recommended …

    Published on 4/23/2012
  • Serada gabapentin GR regulatory update

    Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Product: Serada gabapentin GR Business: Endocrine/Metabolic Depomed said it plans to submit an NDA to FDA next half for Serada extended-release gabapentin tablets to treat …

    Published on 4/23/2012
  • Surepost regulatory update

    Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Surepost (NovoNorm - EU, Prandin - U.S.) repaglinide (SMP-508) Business: …

    Published on 4/23/2012
  • Tekturna regulatory update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tekturna (Rasilez - EU) aliskiren (SPP100) Business: Cardiovascular Novartis updated the label of hypertension drug Tekturna aliskiren in the U.S. to include…

    Published on 4/23/2012
  • Votubia everolimus regulatory update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Votubia everolimus (Afinitor, Certican, Zortress) (RAD001) Business: Cancer The Scottish Medicines Consortium recommended against the use of Novartis' …

    Published on 4/23/2012
  • Xeomin Cosmetic regulatory update

    Merz GmbH & Co. KGaA, Frankfurt, Germany Product: Xeomin Cosmetic (Bocouture - EU) incobotulinumtoxinA (NT 201) Business: Dermatology Merz said Health Canada approved Xeomin Cosmetic incobotulinumtoxinA as a temporary …

    Published on 4/23/2012

< Previous   1  2  3  4  5  6  7  8  9  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Catalent

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?